# INTerpath-004 (NCT06307431)

> A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06307431
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Renal Cell Carcinoma
- Interventions: Intismeran autogene; Pembrolizumab; Placebo
- Enrollment: 272
- Primary outcome: Disease-Free Survival (DFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 12
- Podcasts: 1
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=interpath-004-nct06307431

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06307431", "email": "<work email>"}; the inbox owner confirms by the emailed link.